{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:52:45Z","timestamp":1791312765575,"version":"4.3.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The licensed smallpox vaccine, comprised of infectious vaccinia virus, has associated adverse effects, particularly for immunocompromised individuals. Therefore, safer DNA and protein vaccines are being investigated. The L1 protein, a component of the mature virion membrane that is conserved in all sequenced poxviruses, is required for vaccinia virus entry into host cells and is a target for neutralizing antibody. When expressed by vaccinia virus, the unglycosylated, myristoylated L1 protein attaches to the viral membrane via a C-terminal transmembrane anchor without traversing the secretory pathway. The purpose of the present study was to investigate modifications of the gene expressing the L1 protein that would increase immunogenicity in mice when delivered by a gene gun.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The L1 gene was codon modified for optimal expression in mammalian cells and potential N-glycosylation sites removed. Addition of a signal sequence to the N-terminus of L1 increased cell surface expression as shown by confocal microscopy and flow cytometry of transfected cells. Removal of the transmembrane domain led to secretion of L1 into the medium. Induction of binding and neutralizing antibodies in mice was enhanced by gene gun delivery of L1 containing the signal sequence with or without the transmembrane domain. Each L1 construct partially protected mice against weight loss caused by intranasal administration of vaccinia virus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Modifications of the vaccinia virus L1 gene including codon optimization and addition of a signal sequence with or without deletion of the transmembrane domain can enhance the neutralizing antibody response of a DNA vaccine.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1743-422x-6-28","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T19:14:07Z","timestamp":1236107647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization"],"prefix":"10.1186","volume":"6","author":[{"given":"Kaori","family":"Shinoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari R","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,3]]},"reference":[{"key":"542_CR1","volume-title":"Smallpox and its eradication","author":"F Fenner","year":"1988","unstructured":"Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID: Smallpox and its eradication. first edition. Geneva: World Health Organization; 1988.","edition":"first"},{"key":"542_CR2","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","volume":"281","author":"DA Henderson","year":"1999","unstructured":"Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, et al.: Smallpox as a biological weapon \u2013 Medical and public health management. JAMA-J Amer Med Assoc 1999, 281: 2127-2137. 10.1001\/jama.281.22.2127","journal-title":"JAMA-J Amer Med Assoc"},{"key":"542_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-138-6-200303180-00014","volume":"138","author":"JM Lane","year":"2003","unstructured":"Lane JM, Goldstein J: Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Int Med 2003, 138: 488-493.","journal-title":"Ann Int Med"},{"key":"542_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/375824","volume":"37","author":"VA Fulginiti","year":"2003","unstructured":"Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA: Smallpox vaccination: A review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin Inf Dis 2003, 37: 241-250. 10.1086\/375824","journal-title":"Clin Inf Dis"},{"key":"542_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1086\/375825","volume":"37","author":"VA Fulginiti","year":"2003","unstructured":"Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA: Smallpox vaccination: A review, part II. Adverse events. Clin Inf Dis 2003, 37: 251-271. 10.1086\/375825","journal-title":"Clin Inf Dis"},{"key":"542_CR6","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.vaccine.2006.09.046","volume":"25","author":"I Wiser","year":"2007","unstructured":"Wiser I, Balicer RD, Cohen D: An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Vaccine 2007, 25: 976-984. 10.1016\/j.vaccine.2006.09.046","journal-title":"Vaccine"},{"key":"542_CR7","first-page":"2905","volume-title":"Fields Virology","author":"B Moss","year":"2007","unstructured":"Moss B: Poxviridae: the viruses and their replication. In Fields Virology. Volume 2. Edited by: Knipe DM, Howley PM. Philadelphia: Lippincott Williams & Wilkins; 2007:2905-2946."},{"key":"542_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0065-3527(06)66002-8","volume":"66","author":"RC Condit","year":"2006","unstructured":"Condit RC, Moussatche N, Traktman P: In a nutshell: structure and assembly of the vaccinia virion. Adv Virus Res 2006, 66: 31-124. 10.1016\/S0065-3527(06)66002-8","journal-title":"Adv Virus Res"},{"key":"542_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.virol.2005.09.037","volume":"344","author":"B Moss","year":"2006","unstructured":"Moss B: Poxvirus entry and membrane fusion. Virology 2006, 344: 48-54. 10.1016\/j.virol.2005.09.037","journal-title":"Virology"},{"key":"542_CR10","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1462-5822.2005.00614.x","volume":"7","author":"BM Ward","year":"2005","unstructured":"Ward BM: The longest micron; transporting poxviruses out of the cell. Cellular Microbiology 2005, 7: 1531-1538. 10.1111\/j.1462-5822.2005.00614.x","journal-title":"Cellular Microbiology"},{"key":"542_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","volume":"306","author":"JW Hooper","year":"2003","unstructured":"Hooper JW, Custer DM, Thompson E: Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 2003, 306: 181-195. 10.1016\/S0042-6822(02)00038-7","journal-title":"Virology"},{"key":"542_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1006\/viro.1999.0096","volume":"266","author":"JW Hooper","year":"2000","unstructured":"Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL: DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 2000, 266: 329-339. 10.1006\/viro.1999.0096","journal-title":"Virology"},{"key":"542_CR13","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","volume":"78","author":"C Fogg","year":"2004","unstructured":"Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B: Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 2004, 78: 10230-10237. 10.1128\/JVI.78.19.10230-10237.2004","journal-title":"J Virol"},{"key":"542_CR14","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","volume":"79","author":"S Lustig","year":"2005","unstructured":"Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B: Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 2005, 79: 13454-13462. 10.1128\/JVI.79.21.13454-13462.2005","journal-title":"J Virol"},{"key":"542_CR15","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1128\/jvi.65.10.5631-5635.1991","volume":"65","author":"CF Lai","year":"1991","unstructured":"Lai CF, Gong SC, Esteban M: The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J Virol 1991, 65: 5631-5635.","journal-title":"J Virol"},{"key":"542_CR16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/jvi.66.1.386-398.1992","volume":"66","author":"WE Demkowicz","year":"1992","unstructured":"Demkowicz WE, Maa JS, Esteban M: Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J Virol 1992, 66: 386-398.","journal-title":"J Virol"},{"key":"542_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.virol.2008.08.009","volume":"380","author":"GE Nelson","year":"2008","unstructured":"Nelson GE, Sisler JR, Chandran D, Moss B: Vaccinia virus entry\/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology 2008, 380: 394-401. 10.1016\/j.virol.2008.08.009","journal-title":"Virology"},{"key":"542_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.virol.2006.07.017","volume":"355","author":"P Sakhatskyy","year":"2006","unstructured":"Sakhatskyy P, Wang SX, Chou THW, Lu S: Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 2006, 355: 164-174. 10.1016\/j.virol.2006.07.017","journal-title":"Virology"},{"key":"542_CR19","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1128\/JVI.74.7.3353-3365.2000","volume":"74","author":"CL Lin","year":"2000","unstructured":"Lin CL, Chung CS, Heine HG, Chang W: Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol 2000, 74: 3353-3365. 10.1128\/JVI.74.7.3353-3365.2000","journal-title":"J Virol"},{"key":"542_CR20","doi-asserted-by":"publisher","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","volume":"79","author":"DH Davies","year":"2005","unstructured":"Davies DH, McCausland MM, Valdez C, Huynh D, Hernandez JE, Mu YX, Hirst S, Villarreal L, Felgner PL, Crotty S: Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 2005, 79: 11724-11733. 10.1128\/JVI.79.18.11724-11733.2005","journal-title":"J Virol"},{"key":"542_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1006\/viro.1995.1378","volume":"211","author":"EJ Wolffe","year":"1995","unstructured":"Wolffe EJ, Vijaya S, Moss B: A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 1995, 211: 53-63. 10.1006\/viro.1995.1378","journal-title":"Virology"},{"key":"542_CR22","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/JVI.72.2.1577-1585.1998","volume":"72","author":"C-S Chung","year":"1998","unstructured":"Chung C-S, Hsiao J-C, Chang Y-S, Chang W: A27L protein mediates vaccinia virus interaction with cell surface heparin sulfate. J Virol 1998, 72: 1577-1585.","journal-title":"J Virol"},{"key":"542_CR23","doi-asserted-by":"crossref","first-page":"8374","DOI":"10.1128\/JVI.72.10.8374-8379.1998","volume":"72","author":"JC Hsiao","year":"1998","unstructured":"Hsiao JC, Chung CS, Chang W: Cell surface proteoglycans are necessary for A27L protein- mediated cell fusion: Identification of the N-terminal region of A27L protein as the glycosaminoglycan-binding domain. J Virol 1998, 72: 8374-8379.","journal-title":"J Virol"},{"key":"542_CR24","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.1128\/JVI.73.11.9098-9109.1999","volume":"73","author":"MI Vazquez","year":"1999","unstructured":"Vazquez MI, Esteban M: Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus. J Virol 1999, 73: 9098-9109.","journal-title":"J Virol"},{"key":"542_CR25","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.1128\/JVI.73.10.8750-8761.1999","volume":"73","author":"JC Hsiao","year":"1999","unstructured":"Hsiao JC, Chung CS, Chang W: Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 1999, 73: 8750-8761.","journal-title":"J Virol"},{"key":"542_CR26","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1128\/JVI.78.5.2357-2366.2004","volume":"78","author":"TG Senkevich","year":"2004","unstructured":"Senkevich TG, Ward BM, Moss B: Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol 2004, 78: 2357-2366. 10.1128\/JVI.78.5.2357-2366.2004","journal-title":"J Virol"},{"key":"542_CR27","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.1128\/JVI.00852-08","volume":"82","author":"H Bisht","year":"2008","unstructured":"Bisht H, Weisberg AS, Moss B: Vaccinia virus L1 protein is required for cell entry and membrane fusion. J Virol 2008, 82: 8687-8694. 10.1128\/JVI.00852-08","journal-title":"J Virol"},{"key":"542_CR28","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1128\/jvi.64.12.5988-5996.1990","volume":"64","author":"CA Franke","year":"1990","unstructured":"Franke CA, Wilson EM, Hruby MD: Use of a cell-free system to identify the vaccinia virus L1R gene product as the major late myristylated virion protein M25. J Virol 1990, 64: 5988-5996.","journal-title":"J Virol"},{"key":"542_CR29","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.1073\/pnas.062163799","volume":"99","author":"TG Senkevich","year":"2002","unstructured":"Senkevich TG, White CL, Koonin EV, Moss B: Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc Natl Acad Sci USA 2002, 99: 6667-6672. 10.1073\/pnas.062163799","journal-title":"Proc Natl Acad Sci USA"},{"key":"542_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.virol.2005.07.006","volume":"341","author":"L Aldaz-Carroll","year":"2005","unstructured":"Aldaz-Carroll L, Whitbeck JC, Ponce de Leon M, Lou H, Pannell LK, Lebowitz J, Fogg C, White C, Moss B, Cohen GH, Eisenberg RJ: Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology 2005, 341: 59-71. 10.1016\/j.virol.2005.07.006","journal-title":"Virology"},{"key":"542_CR31","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.vaccine.2006.11.017","volume":"25","author":"JW Hooper","year":"2007","unstructured":"Hooper JW, Golden JW, Ferro AM, King AD: Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 2007, 25: 1814-1823. 10.1016\/j.vaccine.2006.11.017","journal-title":"Vaccine"},{"key":"542_CR32","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1016\/j.vaccine.2008.04.017","volume":"26","author":"JW Golden","year":"2008","unstructured":"Golden JW, Joselyn MD, Hooper JW: Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine 2008, 26: 3507-3515. 10.1016\/j.vaccine.2008.04.017","journal-title":"Vaccine"},{"key":"542_CR33","doi-asserted-by":"publisher","first-page":"8828","DOI":"10.1128\/JVI.79.14.8828-8834.2005","volume":"79","author":"DH Barouch","year":"2005","unstructured":"Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, Kishko MG, Arthur JC, Miura A, Mascola JR, et al.: A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 2005, 79: 8828-8834. 10.1128\/JVI.79.14.8828-8834.2005","journal-title":"J Virol"},{"key":"542_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.virol.2007.06.042","volume":"368","author":"HP Su","year":"2007","unstructured":"Su HP, Golden JW, Gittis AG, Hooper JW, Garboczi DN: Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology 2007, 368: 331-341. 10.1016\/j.virol.2007.06.042","journal-title":"Virology"},{"key":"542_CR35","doi-asserted-by":"publisher","first-page":"10684","DOI":"10.1128\/JVI.77.19.10684-10688.2003","volume":"77","author":"PL Earl","year":"2003","unstructured":"Earl PL, Americo JL, Moss B: Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol 2003, 77: 10684-10688. 10.1128\/JVI.77.19.10684-10688.2003","journal-title":"J Virol"},{"key":"542_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1099\/0022-1317-1-3-399","volume":"1","author":"GS Turner","year":"1967","unstructured":"Turner GS: Respiratory infection of mice with vaccinia virus. J Gen Virol 1967, 1: 399-402. 10.1099\/0022-1317-1-3-399","journal-title":"J Gen Virol"},{"key":"542_CR37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1099\/vir.0.80660-0","volume":"86","author":"M Law","year":"2005","unstructured":"Law M, Putz MM, Smith GL: An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol 2005, 86: 991-1000. 10.1099\/vir.0.80660-0","journal-title":"J Gen Virol"},{"key":"542_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1743-422X-4-22","volume":"4","author":"D Hayasaka","year":"2007","unstructured":"Hayasaka D, Ennis FA, Terajima M: Pathogeneses of respiratory infections with virulent and attenuated vaccinia viruses. Virol J 2007, 4: 22. 10.1186\/1743-422X-4-22","journal-title":"Virol J"},{"key":"542_CR39","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","volume":"78","author":"JW Hooper","year":"2004","unstructured":"Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ichou MA, Steffen SE, Schmaljohn CS, Schmaljohn AL, Jahrling PB: Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 2004, 78: 4433-4443. 10.1128\/JVI.78.9.4433-4443.2004","journal-title":"J Virol"},{"key":"542_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11262-005-0035-7","volume":"33","author":"JW Barrett","year":"2006","unstructured":"Barrett JW, Sun YM, Nazarian SH, Belsito TA, Brunetti CR, McFadden G: Optimization of codon usage of poxvirus genes allows for improved transient expression in mammalian cells. Virus Genes 2006, 33: 15-26. 10.1007\/s11262-005-0035-7","journal-title":"Virus Genes"},{"key":"542_CR41","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1016\/j.vaccine.2006.12.037","volume":"25","author":"CN Fogg","year":"2007","unstructured":"Fogg CN, Americo JL, Lustig S, Huggins JW, Smith SK, Damon I, Resch W, Earl PL, Klinman DM, Moss B: Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 2007, 25: 2787-2799. 10.1016\/j.vaccine.2006.12.037","journal-title":"Vaccine"},{"key":"542_CR42","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","volume":"25","author":"YH Xiao","year":"2007","unstructured":"Xiao YH, Aldaz-Carroll L, Ortiz AM, Whitbeck JC, Alexander E, Lou H, Davis HL, Braciale TJ, Eisenberg RJ, Cohen GH, Isaacs SN: A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 2007, 25: 1214-1224. 10.1016\/j.vaccine.2006.10.009","journal-title":"Vaccine"},{"key":"542_CR43","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1128\/JVI.01854-07","volume":"82","author":"A Berhanu","year":"2008","unstructured":"Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, et al.: Vaccination of BALB\/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol 2008, 82: 3517-3529. 10.1128\/JVI.01854-07","journal-title":"J Virol"},{"key":"542_CR44","first-page":"16.18.11","volume-title":"Current Protocols in Molecular Biology","author":"PL Earl","year":"1998","unstructured":"Earl PL, Moss B: Characterization of recombinant vaccinia viruses and their products. In Current Protocols in Molecular Biology. Volume 2. Edited by: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. New York: Greene Publishing Associates & Wiley Interscience; 1998:16.18.11-16.18.11."},{"key":"542_CR45","first-page":"16.16.11","volume-title":"Current Protocols in Molecular Biology","author":"PL Earl","year":"1998","unstructured":"Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW: Preparation of cell cultures and vaccinia virus stocks. In Current Protocols in Molecular Biology. Volume 2. Edited by: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. New York: John Wiley and Sons; 1998:16.16.11-16.16.13."},{"key":"542_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0022-1759(92)90092-8","volume":"152","author":"MJ Coloma","year":"1992","unstructured":"Coloma MJ, Hastings A, Wims LA, Morrison SL: Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Meth 1992, 152: 89-104. 10.1016\/0022-1759(92)90092-8","journal-title":"J Immunol Meth"},{"key":"542_CR47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0042-6822(03)00063-1","volume":"308","author":"M Husain","year":"2003","unstructured":"Husain M, Weisberg A, Moss B: Topology of epitope-tagged F13L protein, a major membrane component of extracellular vaccinia virions. Virology 2003, 308: 233-242. 10.1016\/S0042-6822(03)00063-1","journal-title":"Virology"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-6-28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T09:59:12Z","timestamp":1630490352000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-6-28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,3]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-6-28","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,3]]},"assertion":[{"value":"10 February 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"28"}}